Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cogent Biosciences (COGT) Research & Development (2017 - 2026)

Cogent Biosciences' Research & Development history spans 10 years, with the latest figure at $75.4 million for Q1 2026.

  • Quarterly Research & Development rose 19.57% to $75.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $282.1 million through Mar 2026, up 16.11% year-over-year, with the annual reading at $269.8 million for FY2025, 15.96% up from the prior year.
  • Research & Development came in at $75.4 million for Q1 2026, roughly flat from $75.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $75.6 million in Q4 2025 to a low of $25.5 million in Q1 2022.
  • The 5-year median for Research & Development is $52.7 million (2024), against an average of $51.4 million.
  • Year-over-year, Research & Development soared 210.12% in 2022 and then increased 8.45% in 2025.
  • Cogent Biosciences' Research & Development stood at $36.7 million in 2022, then soared by 32.6% to $48.7 million in 2023, then grew by 27.35% to $62.0 million in 2024, then grew by 21.78% to $75.6 million in 2025, then dropped by 0.26% to $75.4 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Research & Development are $75.4 million (Q1 2026), $75.6 million (Q4 2025), and $69.0 million (Q3 2025).